Abstract

HLA-restricted T cell responses can induce antitumor effects in cancer patients. Previous human T cell research has largely focused on the few HLA alleles prevalent in a subset of ethnic groups. Here, using a panel of newly developed peptide-exchangeable peptide/HLA multimers and artificial antigen-presenting cells for 25 different class I alleles and greater than 800 peptides, we systematically and comprehensively mapped shared antigenic epitopes recognized by tumor-infiltrating T lymphocytes (TILs) from eight melanoma patients for all their class I alleles. We were able to determine the specificity, on average, of 12.2% of the TILs recognizing a mean of 3.1 shared antigen-derived epitopes across HLA-A, B, and C. Furthermore, we isolated a number of cognate T cell receptor genes with tumor reactivity. Our novel strategy allows for a more complete examination of the immune response and development of novel cancer immunotherapy not limited by HLA allele prevalence or tumor mutation burden.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Kenji Murata

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    Kenji Murata, The University Health Network has filed patent application related to this study on which Kenji Murata is named as an inventor (US16/095,913, US62/813,639, US62/813,642, US62/813,644, US62/813,645, US62/813,647, US62/813,650, US62/813,651, and US62/823,487)..
  2. Munehide Nakatsugawa

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    Munehide Nakatsugawa, The University Health Network has filed patent application related to this study on which Munehide Nakatsugawa is named as an inventor (US16/095,913)..
  3. Muhammed A Rahman

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    Muhammed A Rahman, The University Health Network has filed patent application related to this study on which Muhammed A. Rahman is named as an inventor (US16/095,913)..
  4. Linh T Nguyen

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  5. Douglas G Millar

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  6. David Thomas Mulder

    Clinical Cancer Genomics, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  7. Kenji Sugata

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  8. Hiroshi Saijo

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  9. Yukiko Matsunaga

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  10. Yuki Kagoya

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  11. Tingxi Guo

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  12. Mark Anczurowski

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  13. Chung-Hsi Wang

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  14. Brian D Burt

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  15. Dalam Ly

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  16. Kayoko Saso

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    Kayoko Saso, The University Health Network has filed patent application related to this study on which Kayoko Saso is named as an inventor (US62/813,639, US62/813,642, US62/813,644, US62/813,645, US62/813,647, US62/813,650, US62/813,651, and US62/823,487)..
  17. Alexandra Easson

    Surgical Oncology, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  18. David P Goldstein

    Surgical Oncology, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  19. Michael Reedijk

    Surgical Oncology, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  20. Danny A Ghazarian

    Laboratory Medicine and Pathobiology, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  21. Trevor J Pugh

    Medical Biophysics, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  22. Marcus O Butler

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    Marcus O Butler, Marcus O. Butler has served on advisory boards for Merck, BMS, Novartis, GSK, Immunocore, immunovaccine, Sanofi, and EMD Serono and received research funding for investigator initiated clinical trials from Merck and Takara Bio..
  23. Tak W Mak

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  24. Pamela S Ohashi

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  25. Naoto Hirano

    Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
    For correspondence
    naoto.hirano@uhnresearch.ca
    Competing interests
    Naoto Hirano, Naoto Hirano reports receiving a research grant from and is a consultant for Takara Bio and Otsuka Pharmaceutical and serving on an advisory board for F. Hoffmann-La Roche. The University Health Network has filed patent application related to this study on which Naoto Hirano is named as an inventor (US16/095,913, US62/813,639, US62/813,642, US62/813,644, US62/813,645, US62/813,647, US62/813,650, US62/813,651, and US62/823,487)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9070-4754

Funding

Ontario Institute for Cancer Research (Clinical Investigator Award,IA-039)

  • Naoto Hirano

Province of Ontario

  • Mark Anczurowski

Natural Sciences and Engineering Research Council of Canada (Postgraduate Scholarship)

  • Tingxi Guo

Terry Fox Research Institute (Immunotherapy NeTwork (iTNT) Program)

  • Naoto Hirano

Terry Fox Research Institute (Immunotherapy NeTwork (iTNT) Program)

  • Pamela S Ohashi

Princess Margaret Cancer Centre Innovattion Accelerator Fund

  • Naoto Hirano

Princess Margaret Cancer Foundation

  • Naoto Hirano

Princess Margaret Cancer Foundation

  • Marcus O Butler

Mitacs (Intership)

  • Kenji Murata

Japan Society for the Promotion of Science (Postdoctoral Fellowship for Overseas Researchers and a Guglietti Fellowship)

  • Yuki Kagoya

Province of Ontario

  • Tingxi Guo

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This study was conducted in accordance with the Helsinki Declaration and approved by the Research Ethics Board of the University Health Network, Toronto, Canada (UHN REB# 11-0343, 11-0348). Written informed consent was obtained from all healthy donors who provided peripheral blood samples.

Copyright

© 2020, Murata et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,210
    views
  • 940
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kenji Murata
  2. Munehide Nakatsugawa
  3. Muhammed A Rahman
  4. Linh T Nguyen
  5. Douglas G Millar
  6. David Thomas Mulder
  7. Kenji Sugata
  8. Hiroshi Saijo
  9. Yukiko Matsunaga
  10. Yuki Kagoya
  11. Tingxi Guo
  12. Mark Anczurowski
  13. Chung-Hsi Wang
  14. Brian D Burt
  15. Dalam Ly
  16. Kayoko Saso
  17. Alexandra Easson
  18. David P Goldstein
  19. Michael Reedijk
  20. Danny A Ghazarian
  21. Trevor J Pugh
  22. Marcus O Butler
  23. Tak W Mak
  24. Pamela S Ohashi
  25. Naoto Hirano
(2020)
Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma
eLife 9:e53244.
https://doi.org/10.7554/eLife.53244

Share this article

https://doi.org/10.7554/eLife.53244

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Mykhailo Vladymyrov, Luca Marchetti ... Britta Engelhardt
    Tools and Resources

    The endothelial blood-brain barrier (BBB) strictly controls immune cell trafficking into the central nervous system (CNS). In neuroinflammatory diseases such as multiple sclerosis, this tight control is, however, disturbed, leading to immune cell infiltration into the CNS. The development of in vitro models of the BBB combined with microfluidic devices has advanced our understanding of the cellular and molecular mechanisms mediating the multistep T-cell extravasation across the BBB. A major bottleneck of these in vitro studies is the absence of a robust and automated pipeline suitable for analyzing and quantifying the sequential interaction steps of different immune cell subsets with the BBB under physiological flow in vitro. Here, we present the under-flow migration tracker (UFMTrack) framework for studying immune cell interactions with endothelial monolayers under physiological flow. We then showcase a pipeline built based on it to study the entire multistep extravasation cascade of immune cells across brain microvascular endothelial cells under physiological flow in vitro. UFMTrack achieves 90% track reconstruction efficiency and allows for scaling due to the reduction of the analysis cost and by eliminating experimenter bias. This allowed for an in-depth analysis of all behavioral regimes involved in the multistep immune cell extravasation cascade. The study summarizes how UFMTrack can be employed to delineate the interactions of CD4+ and CD8+ T cells with the BBB under physiological flow. We also demonstrate its applicability to the other BBB models, showcasing broader applicability of the developed framework to a range of immune cell-endothelial monolayer interaction studies. The UFMTrack framework along with the generated datasets is publicly available in the corresponding repositories.

    1. Immunology and Inflammation
    Eugenio Antonio Carrera Silva, Juliana Puyssegur, Andrea Emilse Errasti
    Review Article

    The gut biome, a complex ecosystem of micro- and macro-organisms, plays a crucial role in human health. A disruption in this evolutive balance, particularly during early life, can lead to immune dysregulation and inflammatory disorders. ‘Biome repletion’ has emerged as a potential therapeutic approach, introducing live microbes or helminth-derived products to restore immune balance. While helminth therapy has shown some promise, significant challenges remain in optimizing clinical trials. Factors such as patient genetics, disease status, helminth species, and the optimal timing and dosage of their products or metabolites must be carefully considered to train the immune system effectively. We aim to discuss how helminths and their products induce trained immunity as prospective to treat inflammatory and autoimmune diseases. The molecular repertoire of helminth excretory/secretory products (ESPs), which includes proteins, peptides, lipids, and RNA-carrying extracellular vesicles (EVs), underscores their potential to modulate innate immune cells and hematopoietic stem cell precursors. Mimicking natural delivery mechanisms like synthetic exosomes could revolutionize EV-based therapies and optimizing production and delivery of ESP will be crucial for their translation into clinical applications. By deciphering and harnessing helminth-derived products’ diverse modes of action, we can unleash their full therapeutic potential and pave the way for innovative treatments.